Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

There has been a new antidepressant on the market every two or three years. In 1987, the antidepressant fluoxetine (Prozac) was introduced. It had been tested by the FDA and found to be an ...

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...

TCAs have been on the market the longest — since the 1950s — and may cause more side effects than newer antidepressants. They are usually prescribed only when other antidepressants haven't ...

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on AXSM stock, giving a Buy rating on January 15.Invest with ...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants.

In 2024, the sale of antidepressant drugs in Russia increased by 20%, reaching 16.1 million packages by November, according ...

Alembic Pharmaceuticals has received USFDA approval for its generic version of Brexpiprazole tablets, used to treat major ...

Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Brexpiprazole tablets, used in ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...